A detailed history of Susquehanna International Group, LLP transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 87,501 shares of LXRX stock, worth $62,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,501
Previous 114,126 23.33%
Holding current value
$62,125
Previous $191,000 28.27%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.51 - $2.39 $40,203 - $63,633
-26,625 Reduced 23.33%
87,501 $137,000
Q2 2024

Aug 15, 2024

BUY
$1.54 - $2.28 $159,055 - $235,485
103,283 Added 952.53%
114,126 $191,000
Q1 2024

May 07, 2024

SELL
$1.3 - $3.58 $529,061 - $1.46 Million
-406,970 Reduced 97.4%
10,843 $26,000
Q4 2023

Feb 14, 2024

BUY
$1.0 - $1.53 $89,307 - $136,639
89,307 Added 27.19%
417,813 $639,000
Q3 2023

Nov 14, 2023

SELL
$1.06 - $2.33 $7,368 - $16,195
-6,951 Reduced 2.07%
328,506 $358,000
Q2 2023

Aug 11, 2023

BUY
$2.15 - $3.49 $606,652 - $984,752
282,164 Added 529.46%
335,457 $768,000
Q1 2023

May 16, 2023

BUY
$1.99 - $2.68 $8,831 - $11,893
4,438 Added 9.08%
53,293 $129,000
Q4 2022

Feb 14, 2023

SELL
$1.8 - $2.56 $54,894 - $78,072
-30,497 Reduced 38.43%
48,855 $93,000
Q3 2022

Nov 14, 2022

SELL
$1.94 - $3.43 $28,322 - $50,074
-14,599 Reduced 15.54%
79,352 $190,000
Q2 2022

Aug 15, 2022

SELL
$1.31 - $2.69 $28,762 - $59,061
-21,956 Reduced 18.94%
93,951 $175,000
Q1 2022

May 16, 2022

SELL
$1.95 - $3.89 $38,744 - $77,290
-19,869 Reduced 14.63%
115,907 $242,000
Q4 2021

Feb 14, 2022

BUY
$3.81 - $6.16 $16,866 - $27,270
4,427 Added 3.37%
135,776 $535,000
Q3 2021

Nov 15, 2021

BUY
$3.38 - $5.35 $310,192 - $490,985
91,773 Added 231.89%
131,349 $632,000
Q2 2021

Aug 11, 2021

SELL
$4.12 - $5.87 $206,906 - $294,791
-50,220 Reduced 55.93%
39,576 $182,000
Q4 2020

Feb 16, 2021

BUY
$1.05 - $3.67 $35,021 - $122,409
33,354 Added 59.09%
89,796 $307,000
Q2 2020

Aug 14, 2020

BUY
$1.75 - $2.3 $65,215 - $85,711
37,266 Added 194.34%
56,442 $113,000
Q1 2020

May 15, 2020

SELL
$1.8 - $4.28 $72,466 - $172,308
-40,259 Reduced 67.74%
19,176 $37,000
Q4 2019

Feb 14, 2020

BUY
$3.16 - $5.15 $127,373 - $207,586
40,308 Added 210.74%
59,435 $247,000
Q3 2019

Nov 14, 2019

SELL
$1.2 - $6.66 $15,570 - $86,413
-12,975 Reduced 40.42%
19,127 $58,000
Q2 2019

Aug 16, 2019

SELL
$5.35 - $7.11 $508,517 - $675,805
-95,050 Reduced 74.75%
32,102 $202,000
Q1 2019

May 15, 2019

BUY
$4.36 - $7.94 $129,378 - $235,611
29,674 Added 30.44%
127,152 $707,000
Q4 2018

Feb 14, 2019

BUY
$6.15 - $10.51 $391,183 - $668,509
63,607 Added 187.79%
97,478 $647,000
Q2 2018

Aug 14, 2018

BUY
$7.8 - $13.69 $106,610 - $187,114
13,668 Added 67.65%
33,871 $406,000
Q1 2018

May 15, 2018

SELL
$7.86 - $11.39 $269,275 - $390,210
-34,259 Reduced 62.9%
20,203 $173,000
Q4 2017

Feb 14, 2018

BUY
$8.77 - $12.28 $82,490 - $115,505
9,406 Added 20.88%
54,462 $538,000
Q3 2017

Nov 14, 2017

BUY
$12.17 - $16.3 $548,331 - $734,412
45,056
45,056 $554,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $134M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.